Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index; 16 of the 62 sources its claims cite were checked for support.
Abstract
Elimination of amyloid-ss peptide (Ass) from the brain is poorly understood. After intracerebral microinjections in young mice, (125)I-Ass(1-40) was rapidly removed from the brain (t(1/2) </= 25 minutes), mainly by vascular transport across the blood-brain barrier (BBB). The efflux transport system for Ass(1-40) at the BBB was half saturated at 15.3 nM, and the maximal transport capacity was reached between 70 nM and 100 nM. Ass(1-40) clearance was substantially inhibited by the receptor-associated protein, and by antibodies against LDL receptor-related protein-1 (LRP-1) and alpha(2)-macroglobulin (alpha(2)M). As compared to adult wild-type mice, clearance was significantly reduced in young and old apolipoprotein E (apoE) knockout mice, and in old wild-type mice. There was no evidence that Ass was metabolized in brain interstitial fluid and degraded to smaller peptide fragments and amino acids before its transport across the BBB into the circulation. LRP-1, although abundant in brain microvessels in young mice, was downregulated in older animals, and this downregulation correlated with regional Ass accumulation in brains of Alzheimer's disease (AD) patients. We conclude that the BBB removes Ass from the brain largely via age-dependent, LRP-1-mediated transport that is influenced by alpha(2)M and/or apoE, and may be impaired in AD.
Overview
CoChat Summary
TL;DR
In mice, intracerebrally injected ¹²⁵I-Aβ1-40 is rapidly cleared from brain, mainly by LRP-1-mediated transport across the blood-brain barrier, with clearance influenced by α2M and apoE. LRP-1 downregulation in older mice and in Alzheimer’s disease brain regions correlates with Aβ accumulation, suggesting impaired vascular clearance may contribute to AD.
Key findings
- After intracerebral microinjection in young mice, total brain efflux half-time for ¹²⁵I-Aβ1-40 was 25.5 ± 2.0 minutes versus 239.0 ± 12.5 minutes for [¹⁴C]inulin (9.4-fold difference); BBB transport accounted for 73.8% of efflux, ISF bulk flow 10.7%, and 15.6% remained retained at 60 nM.
- Aβ1-40 clearance was concentration-dependent, half-saturated at 15.3 nM, and maximal between 70 nM and 100 nM. Anti-LRP-1 antibody inhibited clearance by about 55% (58% at 12 nM and 53% at 60 nM), RAP inhibited by 30–44%, and anti-α2M inhibited by 25%; anti-LRP-2 and anti-RAGE had no effect.
- There was no evidence of significant Aβ1-40 degradation in brain ISF before transport: injected peptide was >97% intact, 93.7% remained intact at 60 minutes, and only 4.2–9.9% of brain ¹²⁵I radioactivity was non-TCA-precipitable within 270 minutes; plasma degradation increased from 37.6% to 58.3% between 15 and 120 minutes.
- Clearance was reduced in apoE knockout and older mice: 30% reduction in young apoE KO mice, about 55% and 40% reductions in 9-month-old wild-type and apoE KO mice at 12 nM, and 46% reduction in 9-month-old apoE KO mice at 60 nM. LRP-1-positive brain vessels dropped from 94% in 2-month-old mice to 52% in 9-month-old mice, and reduced LRP-1 staining in AD frontal cortex correlated with regional Aβ accumulation.
Methods
- Male C57BL/6 wild-type and apoE knockout mice at 8–10 weeks and 9–10 months received intracerebral microinjections into the right caudate nucleus of ¹²⁵I-Aβ1-40 (0.05–120 nM) plus [¹⁴C]inulin; clearance was measured from 10 to 300 minutes, with dose and inhibitor studies at 30 minutes.
- Radioactivity was analyzed by TCA precipitation, HPLC, and SDS-PAGE; compartmental modeling separated BBB transport, ISF bulk flow, and brain retention. Inhibitors included anti-LRP-1 R777, RAP, anti-α2M, anti-LRP-2, anti-RAGE, fucoidin, and BCH.
- Immunocytochemistry was performed in mouse brain and human frontal cortex/cerebellum from 3 AD patients and 3 age-matched controls (postmortem 4–7 hours), using antibodies against LRP-1, α2M, Aβ1-40/1-42, and CD105.
Limitations
- The paper does not state limitations explicitly. Evident from the text: the mouse clearance model uses synthetic ¹²⁵I-Aβ1-40 and intracerebral injection, which may not fully reflect endogenous Aβ production and clearance.
- Evident: human data are correlational and based on only 3 AD patients and 3 controls; LRP-1 involvement is inferred from antibody/RAP inhibition and immunostaining rather than direct transport assays.
- Evident: the identity of an alternative low-concentration BBB transport mechanism remains unknown, α2M staining cannot distinguish circulating from microvessel-associated α2M, and age comparisons are limited to young versus 9-month-old mice.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 0 Not valid · 21 Not checked · 114 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Previous studies from our laboratory and others have demonstrated a major role of the BBB in determining the concentrations of A b in the CNS by regulating transport of circulating A b (33, 39, 49-51, 62-66).”
What the sources say
- Partly supportedcites [33] Mackic, 1998, J Clin Invest sourceExperimental — accuracy not yet measured
The Discussion reports transport of circulating Aβ across a human BBB cell model and says that this transport would tend to increase Aβ accumulation in the brain. It does not demonstrate that the BBB has a major role in determining CNS Aβ concentrations in vivo; the paper describes that broader implication as likely. Page numbers are unavailable in our copy. (LLM, conf=0.84)
- Partly supportedcites [39] Zlokovic, 1996, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The paper’s opening summary (page not specified in our copy) reports transport of Aβ–apolipoprotein J complexes across the blood–brain barrier into brain tissue in a guinea pig model. It does not establish that this transport has a major role in determining overall CNS Aβ concentrations, as the citing sentence claims. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [49] Maness, 1994, Life Sci source
- Not checked — no full text of the sourcecites [50] Poduslo, 1997, Neurobiol Dis source
- Not checked — no full text of the sourcecites [51] Martel, 1997, J Neurochem source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Binding/uptake studies in mouse embryonic fibroblasts (wild type and deficient in LRP-1), confirmed that free A b is not a ligand for LRP-1 (37, 45).”
What the sources say
- Partly supportedcites [37] Narita, 1997, J Neurochem sourceExperimental — accuracy not yet measured
The Abstract and Discussion report that free Aβ degradation was not inhibited by RAP and describe it as LRP-independent. But Table 1 tested free Aβ in human U87 glioblastoma cells; the mouse embryonic fibroblast comparison tested Aβ complexed with α2-macroglobulin, not free Aβ. Thus the paper supports the LRP-independent uptake conclusion, but not the claim that the fibroblast studies confirmed it. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [45] Kounnas, 1995, Cell source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Because normal aging is associated with A b accumulation in the brain (1)”
What the sources say
- Supportedcites [1] Wisniewski, 1997, Neurobiol Dis source
The section on the amyloid cascade hypothesis says that extensive Aβ-containing preamyloid deposits can be found in aged individuals with no reported clinical symptoms. This supports the claim that brain Aβ accumulation is associated with normal aging; the paper does not say it occurs in every older person. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This makes re-entry of radiolabeled A b into the brain very unlikely, because the blood-to-brain transport of A b normally operates down the concentration gradient (39, 62-65).”
What the sources say
- Partly supportedcites [39] Zlokovic, 1996, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The paper’s study summary (page not identified in our copy) reports transport of Aβ–apolipoprotein J complexes from blood into brain parenchyma. It does not say that this transport normally follows a concentration gradient or that re-entry of radiolabeled Aβ is unlikely. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [62] Zlokovic, 1993, Biochem Biophys Res Commun source
- Not checked — no full text of the sourcecites [63] Ghilardi, 1996, Neuroreport source
- Not checked — no full text of the sourcecites [64] Shayo, 1997, Life Sci source
- Partly supportedcites [65] Martel, 1996, Neurosci Lett sourceExperimental — accuracy not yet measured
The discussion passage in our copy (labeled Abstract; page unavailable) says that a lower soluble Aβ42 concentration on the brain side of the BBB would provide a thermodynamic impetus for transport from capillaries into brain. It does not establish that blood-to-brain transport normally operates down a concentration gradient or that re-entry of radiolabeled Aβ is very unlikely; the study also observed uptake of radiolabeled Aβ in perfused guinea-pig brains. (LLM, conf=0.80)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“RAP, a chaperone protein that facilitates proper folding and subsequent trafficking of LRP-1 and LRP-2 (69), also inhibited A b clearance.”
What the sources say
- Partly supportedcites [69] Bu, 1996, J Biol Chem sourceExperimental — accuracy not yet measured
The citation is attached to the description of RAP as a folding and trafficking chaperone, not to the citing authors’ statement that RAP inhibited Aβ clearance. The paper’s Discussion supports that role for LRP, but does not establish it for the separate receptor LRP-2; its use of “LRP2” denotes a domain of LRP. (LLM, conf=0.89)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
92 more claims
Create a free account to see all 147 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 30
- Probably not a substantial claim. 25
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“For example, transport studies using radiolabeled and unlabeled Alzheimer's A 𝛃 peptide have shown that under physiological conditions, the perivascular ISF flow contributes to 15-20% of A 𝛃 clearance from the mouse brain (58, 535, 659), whereas 8085% is removed by transvascular BBB transport.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 binds Alzheimer's A 𝛃 toxin and mediates its brain-to-blood clearance (58, 137, 535, 561).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several groups have reported that trans-BBB efflux of Aβ into peripheral blood circulation is one of the main pathways of physiological clearance with ApoE, ApoJ, and ApoA1 as chaperones27,31,32.”
From Brain-targeted drug delivery by manipulating protein corona functions (2019) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 and LRP2 are expressed in brain endothelium and colocalize mainly on the abluminal side of the BBB in humans and rodents (137, 404, 535, 607, 682).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“whereas 8085% is removed by transvascular BBB transport.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results · p. 5
“The HPLC analysis of brain radioactivity confirmed the TCA results by indicating that 93.7% of the peptide remains intact in brain ISF at 60 minutes (Figure 3b, right).”
§ Figure 3 · p. 6
“( b ) Left panel shows HPLC elution profile of brain tissue 60 minutes after intracerebral microinjection of 125 I-A b 1-40 (60 nM). Separation was performed for 30 mg of brain tissue on a reverse-phase HPLC column, using a 30-minute linear gradient of 25-83% acetonitrile in 0.1% TFA, pH 2. 125 I-A b 1-40 eluted at 52%, corresponding to the elution time of A b 1-40 standard. Right panel shows SDS-PAGE analysis”
Citations
Cites
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · cited 10×
“No anti-Aβ1-40–positive or Aβ1-42–positive staining was seen in either AD or control tissues.”
BackgroundInfluentialCorrelative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · cited 2×
“Because normal aging is associated with Aβ accumulation in the brain (1), and there is a significant, timedependent, and progressive accumulation of the peptide with age in transgenic APP animals (54, 55), we postulated that Aβ clearance mechanisms might be impaired in older animals, and are also possibly impaired in…”
BackgroundRAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012 · cited 9×
“In contrast, anti–LRP-2 Ab (Figure 4b) and anti-RAGE Ab (Figure 4c) did not affect Aβ clearance.”
BackgroundInfluentialIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
BackgroundSelf-citationHolcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386 · cited 1×
“Because normal aging is associated with Aβ accumulation in the brain (1), and there is a significant, timedependent, and progressive accumulation of the peptide with age in transgenic APP animals (54, 55), we postulated that Aβ clearance mechanisms might be impaired in older animals, and are also possibly impaired in…”
BackgroundAlzheimer's Disease--Genotypes, Phenotype, and Treatments
Selkoe, D. J. (1997) · Science · doi:10.1126/science.275.5300.630 · Cited by 875 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
BackgroundIwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H.-J., Hama, E., Sekine-Aizawa, Y., et al. (2000) · Nature Medicine · doi:10.1038/72237 · Cited by 867 · cited 8×
“However, the physiological relevance of the proposed degradation mechanism for Aβ1-42 (28) remains unclear, because the peptide was studied at extremely high concentrations (∼ 240 μM) that are not found even in brains with severe β-amyloidosis (30).”
BackgroundMethodResultInfluentialThe cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease
Selkoe, D. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01363-4 · Cited by 862 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
Background
Research works printed but not linked: 4
- Suzuki, 1994, Am J Pathol, 145, 452
- Urmoneit, 1997, Lab Invest, 77, 157
- Yamada, 1991, Am J Physiol, 261, H1197
- Kounnas, 1994, In Vivo, 8, 343
Cited by
Items 301–400 of 1,448
Xu, J., & Ikezu, T. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-008-9136-0 · Cited by 119
“…transport across vessel walls into the circulation mediated by blood vessel wall-expressed low-density lipoprotein receptor-related protein-1 (LRP-1; Shibata et al. 2000; Lam et al. 2001), clearance from brain via binding of Aβ to soluble LRP-1 circulating in blood (acting as an endogenous…”
BackgroundSynaptic Dysfunction in Alzheimer’s Disease: Aβ, Tau, and Epigenetic Alterations
Li, K., Wei, Q., Liu, F., Hu, F., Xie, A., Zhu, L., & Liu, D. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0533-3 · Cited by 143
“For instance, the low-density lipoprotein receptor-related protein 1 (LRP1), which is abundantly expressed in various brain cell types, has been implicated in mediating Aβ transcytosis across the blood-brain barrier (BBB) [38].”
BackgroundTamaki, C., Ohtsuki, S., Iwatsubo, T., Hashimoto, T., Yamada, K., Yabuki, C., & Terasaki, T. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0208-7 · Cited by 119
“Recent studies suggest that LRP-1 is involved in the brain-to-blood clearance of Ab(1Y40) associated with LRP-1 ligands, such as apoE and a2-macroglobulin ( 14 ,35), and also in the clearance of free Ab(1Y40) (15).”
BackgroundInfluentialHemming, M. L., Selkoe, D. J., & Farris, W. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.01.004 · Cited by 128
Yamada, K., Yabuki, C., Seubert, P., Schenk, D., Hori, Y., Ohtsuki, S., Terasaki, T., Hashimoto, T., & Iwatsubo, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2021-09.2009 · Cited by 117
“1B), in agreement with the previous reports (Shibata et al., 2000; Shiiki et al., 2004; Ito et al., 2007).”
ResultChen, Y., He, Y., Han, J., Wei, W., & Chen, F. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1258640 · Cited by 116
Schulz, J., Hartz, A. M. S., & Bauer, B. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000025 · Cited by 122
“Abcb1 cooperates with low-density lipoprotein receptor-related protein-1 (LRP1) located in the abluminal membrane of the brain capillary endothelium where it shuttles Ab from the brain into brain capillary endothelial cells (Shibata et al., 2000; Deane et al., 2004; Storck et al., 2018).”
BackgroundABCG2- and ABCG4-Mediated Efflux of Amyloid-β Peptide 1-40 at the Mouse Blood-Brain Barrier
Do, T. M., Noel-Hudson, M.-S., Ribes, S., Besengez, C., Smirnova, M., Cisternino, S., Buyse, M., Calon, F., Chimini, G., Chacun, H., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-112189 · Cited by 109
“…by several influx and efflux transporters at the solute carrier (SLC) and ATP-binding cassette (ABC transporters [6]. receptor-related protein-1 (LRP-1) [7, 8] is responsible for the efflux of A (cid:1) from brain to the BCECs, while ABCB1 (P-glycoprotein) transports it from the BCECs to blood [9–11].”
Paris, D., Bachmeier, C., Patel, N., Quadros, A., Volmar, C.-H., Laporte, V., Ganey, J., Beaulieu-Abdelahad, D., Ait-Ghezala, G., Crawford, F., et al. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00180 · Cited by 114
“The receptor for advanced glycation end products (RAGE) has been identified as the main receptor responsible for the influx of circulating Aβ to the brain whereas the lipoprotein receptor (LRP-1) has been identified as the receptor mediating the efflux of Aβ from the brain into the circulation (36,37).”
BackgroundVan Gool, B., Storck, S. E., Reekmans, S. M., Lechat, B., Gordts, P. L. S. M., Pradier, L., Pietrzik, C. U., & Roebroek, A. J. M. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1594-2 · Cited by 114
Meningeal Lymphatics: From Anatomy to Central Nervous System Immune Surveillance
Papadopoulos, Z., Herz, J., & Kipnis, J. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900838 · Cited by 110
Nikolic, W. V., Hou, H., Town, T., Zhu, Y., Giunta, B., Sanberg, C. D., Zeng, J., Luo, D., Ehrhart, J., Mori, T., et al. (2008) · Stem Cells and Development · doi:10.1089/scd.2008.0018 · Cited by 113
“Experiments in rat models demonstrating clearance of A 1-40 peptide from the brain via the blood–brain barrier (BBB) support this notion [62–64].”
Apolipoprotein E, Amyloid, and Alzheimer Disease
Bales, K. R. (2002) · Molecular Interventions · doi:10.1124/mi.2.6.363 · Cited by 113
Cerebral amyloid angiopathy: Pathogenesis and effects on the ageing and Alzheimer brain
Weller, R. O., & Nicoll, J. A. R. (2003) · Neurological Research · doi:10.1179/016164103101202057 · Cited by 114
Sun, M., Ma, K., Wen, J., Wang, G., Zhang, C., Li, Q., Bao, X., & Wang, H. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190872 · Cited by 113
“The former is responsible for brain-to-blood efflux, while the latter facilitates blood-to-brain influx [86, 87] Implicating a role for microbial and inflammatory modulation of A (cid:2) transport across the BBB, LPS has been shown to increase A (cid:2) influx and decrease A (cid:2) efflux via decreased…”
Vascular Hypothesis of Alzheimer Disease: Topical Review of Mouse Models
Scheffer, S., Hermkens, D. M. A., van der Weerd, L., de Vries, H. E., & Daemen, M. J. A. P. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.311911 · Cited by 102
Cai, Y., Zhang, Y., Leng, S., Ma, Y., Jiang, Q., Wen, Q., Ju, S., & Hu, J. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106426 · Cited by 135
“A study in mice has demonstrated that decreasing the number of endothelial transporters leads to a 55% decrease in A β clearance (Shibata et al., 2000).”
Extra-virgin olive oil attenuates amyloid-β and tau pathologies in the brains of TgSwDI mice
Qosa, H., Mohamed, L. A., Batarseh, Y. S., Alqahtani, S., Ibrahim, B., LeVine, H., Keller, J. N., & Kaddoumi, A. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.07.022 · Cited by 105
“Because Aβ40 and Aβ42 share the same clearance pathways [34,35], in this study, Aβ40 was used in the BCI experiments for practicality reasons as it has much faster clearance rate than Aβ42 [36].”
An Integrated View on Vascular Dysfunction in Alzheimer’s Disease
Klohs, J. (2019) · Neurodegenerative Diseases · doi:10.1159/000505625 · Cited by 111
Zhang, J., Zhan, Z., Li, X., Xing, A., Jiang, C., Chen, Y., Shi, W., & An, L. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00395 · Cited by 104
“Animal studies found that about 75% of extracellular Aβ is cleared by the blood–brain barrier, with only about 10% being cleared by interstitial fluid bulk flow (Shibata et al., 2000; Zlokovic and Frangione, 2003).”
BackgroundFišar, Z. (2022) · Biomolecules · doi:10.3390/biom12111676 · Cited by 120
“Enhancing LRP1-mediated Aβ clearance pathways is a promising therapeutic strategy for AD [187,188].”
BackgroundSilverberg, G. D., Miller, M. C., Messier, A. A., Majmudar, S., Machan, J. T., Donahue, J. E., Stopa, E. G., & Johanson, C. E. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181c8ad2f · Cited by 111
“Solute clearance is initiated by diffusion and the bulk flow of interstitial fluid to the perivascular, ventricular, and subarachnoid cerebrospinal fluid (13, 42, 43).”
BackgroundDecreased CSF clearance and increased brain amyloid in Alzheimer’s disease
Li, Y., Rusinek, H., Butler, T., Glodzik, L., Pirraglia, E., Babich, J. W., Mozley, P. D., Nehmeh, S. A., Pahlajani, S. S., Wang, X. H., et al. (2022) · Fluids and Barriers of the CNS · doi:10.1186/s12987-022-00318-y · Cited by 121
“Introduction Two decades after it was hypothesized that the amyloidosis of sporadic Alzheimer’s disease (AD) is mechanistically related to the impaired clearance of Aβ from the parenchyma [1, 2], there is limited understanding of the pathophysiology of brain Aβ clearance in sporadic AD [3–5].”
BackgroundGosselet, F., Candela, P., Sevin, E., Berezowski, V., Cecchelli, R., & Fenart, L. (2009) · Brain Research · doi:10.1016/j.brainres.2008.10.036 · Cited by 97
“Moreover, in vivo, ApoE can interact with A β peptide to form a complex which is recognized by receptors from the LDLR family for transcytosis across the BBB (Jaeger and Pietrzik, 2008; Shibata et al., 2000).”
BackgroundErickson, M. A., Morofuji, Y., Owen, J. B., & Banks, W. A. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.213074 · Cited by 110
“Efflux systems at the BBB have been characterized for compounds whose accumulation in the CNS would lead to neuronal damage such as amyloid b (Shibata et al., 2000), prostaglandin E2 (Akanuma et al.”
BackgroundABC Transporters and the Alzheimer’s Disease Enigma
Wolf, A., Bauer, B., & Hartz, A. M. S. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00054 · Cited by 103
Zhao, Y., Li, D., Zhao, J., Song, J., & Zhao, Y. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2015-0069 · Cited by 101
“LRP-1 is one of the most important transporters of Aβ (both Aβ1–40 and Aβ1–42) in CNS, mediating its efflux across the BBB (Shibata et al., 2000; Jaeger et al., 2009a,b; Pflanzner et al., 2011).”
BackgroundInflammatory Cascade in Alzheimer’s Disease Pathogenesis: A Review of Experimental Findings
de Oliveira, J., Kucharska, E., Garcez, M. L., Rodrigues, M. S., Quevedo, J., Moreno-Gonzalez, I., & Budni, J. (2021) · Cells · doi:10.3390/cells10102581 · Cited by 102
“[135] and other authors pointed out that brain Aβ is mainly cleared across BBB via LRP-1.”
BackgroundDelineating the Mechanism of Alzheimer’s Disease Aβ Peptide Neurotoxicity
Cappai, R., & Barnham, K. J. (2008) · Neurochemical Research · doi:10.1007/s11064-007-9469-8 · Cited by 108
“The LRP, apoE and a2M molecules probably modulate Ab toxicity via the clearance of apoE:Ab, a2M:Ab complexes or Ab alone from the brain and hence reduce Ab levels [52, 53].”
BackgroundKyrtsos, C. R., & Baras, J. S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139574 · Cited by 108
“Clearance of Aβ by LRP-1 has also been shown to decrease by nearly 55% during aging and is believed to be secondary to loss of brain endothelial cells [19].”
BackgroundInfluentialKaur, J., Fahmy, L. M., Davoodi‐Bojd, E., Zhang, L., Ding, G., Hu, J., Zhang, Z., Chopp, M., & Jiang, Q. (2021) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2021.665803 · Cited by 117
Bedse, G., Romano, A., Lavecchia, A. M., Cassano, T., & Gaetani, S. (2014) · Journal of Alzheimer’s Disease · doi:10.3233/jad-141635 · Cited by 102
The unsolved relationship of brain aging and late-onset Alzheimer disease
Kern, A., & Behl, C. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.07.016 · Cited by 117
Evidence of a Role for Lactadherin in Alzheimer's Disease
Boddaert, J., Kinugawa, K., Lambert, J., Boukhtouche, F., Zoll, J., Merval, R., Blanc‐Brude, O., Mann, D. M. A., Berr, C., Vilar, J., et al. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.060664 · Cited by 114
A Role for P-Glycoprotein in Clearance of Alzheimer Amyloid ? -Peptide from the Brain
Wang, W., M. Bodles-Brakhop, A., & W. Barger, S. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160314151012 · Cited by 107
“Aβ binds to low-density lipoprotein receptor-related protein-1 (LRP1) on the basolateral membranes of brain capillary endothelial cells (BCEC), which compose the BBB (9, 10).”
BackgroundMonro, O. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00317-7 · Cited by 107
How Can Insulin Resistance Cause Alzheimer’s Disease?
Yoon, J. H., Hwang, J., Son, S. U., Choi, J., You, S.-W., Park, H., Cha, S.-Y., & Maeng, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043506 · Cited by 116
“blood toward the brain to increase the amount of Aβ in the brain tissue, whereas LRP-1 mediates the movement from the brain to the blood [93,94] (Figure 4).”
BackgroundBlood-brain barrier disruption: a culprit of cognitive decline?
Che, J., Sun, Y., Deng, Y., & Zhang, J. (2024) · Fluids and Barriers of the CNS · doi:10.1186/s12987-024-00563-3 · Cited by 125
“A significant reduction in LRP1 expression in the AD brain microvascular ECs has also been validated in several clinical studies [251–253].”
BackgroundThe blood–brain barrier: a help and a hindrance
Rust, R., Yin, H. R., Buil, B. A., Sagare, A. P., & Kisler, K. (2025) · Brain · doi:10.1093/brain/awaf068 · Cited by 120
“100,103,107 More recently, LRP1 in vascular mural cells has also been described to regulate cerebrovascular integrity and function in an APOE genotype dependent manner.”
Boche, D., & Nicoll, J. A. R. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00134.x · Cited by 104
“Evidence for several potential mechanisms by which Ab is normally eliminated from the brain has emerged, including (i) by cellular mechanisms involving microglia (85, 90); (ii) by enzymatic degradation (eg, neprilysin and insulin degrading enzyme) (54, 91); (iii) by transport across the blood–brain barrier mediated by…”
BackgroundNishida, Y., Ito, S., Ohtsuki, S., Yamamoto, N., Takahashi, T., Iwata, N., Jishage, K.-I., Yamada, H., Sasaguri, H., Yokota, S., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.054056 · Cited by 103
Autoantibodies to Annexin XI-A and Other Autoantigens in the Diagnosis of Breast Cancer
Fernández-Madrid, F., Tang, N., Alansari, H., Granda, J. L., Tait, L. R., Amirikia, K. C., Moroianu, M., Wang, X., & Karvonen, R. L. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0932 · Cited by 106
“However, a role for gelsolin has also been suggested in the pathogenesis of Parkinson’s disease and in the Finnish-type familial amyloidosis and related conditions (78, 79), and the pan-proteinase inhibitor -2-macroglobulin has been widely implicated in the pathogenesis of Alzheimer’s disease (80, 81).”
Blood–brain barrier and blood–cerebrospinal fluid barrier in normal and pathological conditions
Ueno, M., Chiba, Y., Murakami, R., Matsumoto, K., Kawauchi, M., & Fujihara, R. (2016) · Brain Tumor Pathology · doi:10.1007/s10014-016-0255-7 · Cited by 118
Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer’s disease
Dorey, E., Chang, N., Liu, Q. Y., Yang, Z., & Zhang, W. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1422-z · Cited by 116
“ApoE is also involved in the clearance of Aβ across the blood-brain barrier (BBB), a process mediated by both astrocytes and microglia through the interaction of Aβ-ApoE complexes with receptors for ApoE, particularly LRP1([100-103]).”
InfluentialThe Blood–Brain Barrier in Alzheimer's Disease
Sharma, H. S., Castellani, R. J., Smith, M. A., & Sharma, A. (2012) · International review of neurobiology · doi:10.1016/b978-0-12-386986-9.00003-x · Cited by 113
Physiologic and anatomic characterization of the brain surface glia barrier of Drosophila
DeSalvo, M. K., Mayer, N., Mayer, F., & Bainton, R. J. (2011) · Glia · doi:10.1002/glia.21147 · Cited by 116
“For example, BBB transporters are implicated in the accumulation of (1) beta amyloid during Alzheimer’s disease (LRP1 transporter; Shibata et al., 2000) and (2) toxins contributing to Parkinson’s (MDR1 transporter; Kortekaas et al., 2005).”
BackgroundApolipoprotein E and Alzheimer disease
Huang, Y. (2006) · Neurology · doi:10.1212/01.wnl.0000192102.41141.9e · Cited by 106
Effect of Different Anti-Aβ Antibodies on Aβ Fibrillogenesis as Assessed by Atomic Force Microscopy
Legleiter, J. A., Czilli, D. L., Gitter, B. D., Demattos, R. B., Holtzman, D. M., & Kowalewski, T. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.11.019 · Cited by 119
Self-citationNeurovascular Pathways and Alzheimer Amyloid β-peptide
Zlokovic, B. V., Deane, R., Sallstrom, J., Chow, N., & Miano, J. M. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00103.x · Cited by 104
“Strategies to directly enhance the binding of Aβ to LRP1 (10) or to its lipoprotein receptors ligands/Aβ chaperones (51), may offer promising therapeutic avenues in future giving the prevailing role of LRP1 in Aβ clearance across the BBB (10, 48) and on astrocytes (30).”
BackgroundInfluentialApicobasal polarity of brain endothelial cells
Worzfeld, T., & Schwaninger, M. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x15608644 · Cited by 105
Potential Pathways for CNS Drug Delivery Across the Blood-Cerebrospinal Fluid Barrier
Strazielle, N., & Ghersi-Egea, J.-F. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160726112115 · Cited by 98
“The receptor was immunodetected in mouse brain microvessels [110].”
BackgroundAluminum complexing enhances amyloid β protein penetration of blood–brain barrier
Banks, W. A., Niehoff, M. L., Drago, D., & Zatta, P. F. (2006) · Brain Research · doi:10.1016/j.brainres.2006.07.112 · Cited by 119
Li, X., & Buxbaum, J. N. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-79 · Cited by 99
“The majority of clearance occurs via transport through the BBB [73].”
BackgroundAn overview of protein–polymer particles
Boyer, C. A., Huang, X. C., Whittaker, M. R., Bulmuş, V., & Davis, T. P. (2011) · Soft Matter · doi:10.1039/c0sm00412j · Cited by 116
Zhang, J., Wu, X., Qin, C., Qi, J., Ma, S., Zhang, H., Kong, Q., Chen, D., Ba, D., & He, W. (2003) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.07.005 · Cited by 103
Endothelin-Converting Enzyme-2 Is Increased in Alzheimer’s Disease and Up-Regulated by Aβ
Palmer, J. C., Baig, S., Kehoe, P. G., & Love, S. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.081054 · Cited by 113
Zhang, J.-X., Xing, J.-G., Wang, L.-L., Jiang, H.-L., Guo, S.-L., & Liu, R. (2017) · Molecules · doi:10.3390/molecules22030334 · Cited by 101
“In addition, brain-derived Aβ in the plasma are cleared by low density lipoprotein receptor related protein 1 (LRP-1)-mediated scavenging signal transduction [39].”
BackgroundBrain Insulin Impairs Amyloid-β(1-40) Clearance from the Brain
Shiiki, T., Ohtsuki, S., Kurihara, A., Naganuma, H., Nishimura, K., Tachikawa, M., Hosoya, K.-I., & Terasaki, T. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2236-04.2004 · Cited by 100
“Furthermore, the elimination rate of A (1– 40) was reduced in aged rats, as it was in aged mice (Shibata et al., 2000).”
BackgroundMethodInfluentialErickson, M. A., Hansen, K., & Banks, W. A. (2012) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.07.003 · Cited by 98
“Deficits in both LRP-1 and Pgp at the BBB have been proposed to cause Ab accumulation in the brain (Cirrito et al., 2005; Hartz et al., 2010; Jaeger et al., 2009a,b; Shibata et al., 2000).”
InfluentialImmunotherapy for Alzheimer's disease
Dodel, R. C., Hampel, H. J., & Du, Y. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00349-1 · Cited by 107
Cerebral amyloid angiopathy: pathogenetic mechanisms and link to dense amyloid plaques
Kumar‐Singh, S. (2008) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2007.00380.x · Cited by 94
“One of these mechanisms is a direct Ab transport across the blood– brain barrier (BBB) mediated by low-density lipoprotein receptor-related protein-1 (LRP-1), which in turn is influenced by a2macroglobulin and apolipoprotein E (ApoE) (Shibata et al. 2000).”
BackgroundInfluentialDisruption of blood-brain barrier in Alzheimer disease pathogenesis
Kook, S.-Y., Seok Hong, H., Moon, M., & Mook-Jung, I. (2013) · Tissue Barriers · doi:10.4161/tisb.23993 · Cited by 95
“Clearance of Alzheimer’s amyloid-ss(1-40) peptide from brain by LDL receptorrelated protein-1 at the blood-brain barrier.”
BackgroundP‐glycoprotein: a role in the export of amyloid‐β in Alzheimer's disease?
Chai, A. B., Leung, G. K. F., Callaghan, R., & Gelissen, I. C. (2020) · The FEBS Journal · doi:10.1111/febs.15148 · Cited by 96
Links Between the Pathology of Alzheimer's Disease and Vascular Dementia
Sadowski, M., Pankiewicz, J. E., Scholtzova, H., Li, Y., Quartermain, D., Duff, K., & Wısnıewskı, T. (2004) · Neurochemical Research · doi:10.1023/b:nere.0000023612.66691.e6 · Cited by 115
“Evidence demonstrating impairment of this process with aging implicates primary BBB dysfunction as a factor contributing to the development of sporadic AD (71,73,74).”
BackgroundInfluentialYamanaka, Y., Faghihi, M. A., Magistri, M., Alvarez-Garcia, O., Lotz, M., & Wahlestedt, C. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.011 · Cited by 99
“Recently, LRP1 has been implicated in the systemic clearance of AD amyloid-beta (Ab), and the level of LRP1 expression is critical for AD progression (Deane et al., 2008; Holtzman et al., 2012; Kang et al., 2000; Liu et al., 2007; Shibata et al., 2000).”
BackgroundAalinkeel, R., Kutscher, H. L., Singh, A. K., Cwiklinski, K., Khechen, N., Schwartz, S. A., Prasad, P. N., & Mahajan, S. D. (2017) · Journal of drug targeting · doi:10.1080/1061186x.2017.1354002 · Cited by 100
“Angiopep-2 provides a non-invasive and flexible platform for transporting drugs or biologically active molecules into the CNS [29–31], and was incorporated into the NP surface to enable the NP to cross the BBB as well as homing on to the glial cells which also express Angiopep2 receptors.”
BackgroundUnderstanding the Pathophysiology of Cerebral Amyloid Angiopathy
Gatti, L., Tinelli, F., Scelzo, E., Arioli, F., Di Fede, G., Obici, L., Pantoni, L., Giaccone, G., Caroppo, P., Parati, E. A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103435 · Cited by 90
“It is also well-known that Aβ accumulation in the cerebral vessels interferes with the BBB ability to clear Aβ from the CNS [130].”
BackgroundLiao, M.-C., & Van Nostrand, W. E. (2010) · Biochemistry · doi:10.1021/bi901994d · Cited by 92
“Several major pathways for Aβ clearance have been identified including receptor-mediated cellular uptake, blood-brain barrier transport (4, 5), and direct proteolytic degradation.”
BackgroundIto, S., Ohtsuki, S., Nezu, Y., Koitabashi, Y., Murata, S., & Terasaki, T. (2011) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-8-20 · Cited by 97
“Ab is normally produced by neurons and cleared through degradation by proteinases within the brain [2-4], as well as through elimination from the brain to the circulating blood via an efflux transport system at the blood-brain barrier (BBB) [5,6].”
BackgroundSeppala, T. T., Herukka, S.-K., Hanninen, T., Tervo, S., Hallikainen, M., Soininen, H., & Pirttila, T. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.205757 · Cited by 95
The pathobiology of neurovascular aging
Santisteban, M. M., & Iadecola, C. (2025) · Neuron · doi:10.1016/j.neuron.2024.12.014 · Cited by 111
Best, J. D., Jay, M. T., Otu, F., Ma, J., Nadin, A. J., Ellis, S., Lewis, H. D., Pattison, C., Reilly, M., Harrison, T., et al. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.081174 · Cited by 103
“It has been demonstrated that removal of A (1-40) from the brain to the plasma is very rapid and appears to be regulated by LRP (Shibata et al., 2000).”
BackgroundInfluentialGuo, Y.-X., He, L., Zhang, M., Wang, F., Liu, F., & Peng, W. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.01.041 · Cited by 103
Glutamine Synthetase: Role in Neurological Disorders
Jayakumar, A., & Norenberg, M. D. (2016) · Advances in neurobiology · doi:10.1007/978-3-319-45096-4_13 · Cited by 107
Blood–Brain Barrier Breakdown in Neuroinflammation: Current In Vitro Models
Brandl, S., & Reindl, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612699 · Cited by 104
“Receptors mediate the transport of protein ligands, such as amyloid-beta (Aβ), transferrin, insulin, and apolipoprotein E [17,18].”
BackgroundBlood will out: vascular contributions to Alzheimer’s disease
Strickland, S. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97509 · Cited by 91
Liu, L., Wan, W., Xia, S., Kalionis, B., & Li, Y. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2014.05.004 · Cited by 107
Mouse Models to Study the Effect of Cardiovascular Risk Factors on Brain Structure and Cognition
Bink, D. I., Ritz, K., Aronica, E., van der Weerd, L., & Daemen, M. J. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.140 · Cited by 96
Is RAGE Still A Therapeutic Target For Alzheimer’s Disease?
Deane, R. J. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.51 · Cited by 94
Kulstad, J. J., McMillan, P. J., Leverenz, J. B., Cook, D. G., Green, P. S., Peskind, E. R., Wilkinson, C. W., Farris, W., Mehta, P. D., & Craft, S. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.2.139 · Cited by 97
“Sequestration presumably may result from reduced efflux of Ab from brain to plasma, a process linked to the LDL receptor-related protein-1 (37).”
BackgroundYerbury, J. J., Kumita, J. R., Meehan, S., Dobson, C. M., & Wilson, M. R. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807242200 · Cited by 95
Boada, M., Anaya, F., Ortiz, P., Olazarán, J., Shua-Haim, J. R., Obisesan, T. O., Hernández, I., Muñoz, J., Buendia, M., Alegret, M., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160565 · Cited by 94
“Studies conducted in animal models showed that the elimination half-life of A between CSF and plasma is about 30 minutes [12, 15, 16].”
BackgroundPhysiological Roles of Amyloid-?? and Implications for its Removal in Alzheimer???s Disease
Bishop, G. M., & Robinson, S. R. (2004) · Drugs & Aging · doi:10.2165/00002512-200421100-00001 · Cited by 94
Aluise, C. D., Sowell, R. A., & Butterfield, D. A. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.07.008 · Cited by 94
“Brain-derived Aβ is thought to infiltrate plasma via the actions of two transporters at the blood brain barrier (BBB), low-density lipoprotein-related protein 1 (LRP1) [110] and pglycoprotein [111], as well as bulk flow from CSF/interstitial fluid to plasma (Figure 3).”
BackgroundDifferential cerebral deposition of IDE and NEP in sporadic and familial Alzheimer's disease
Dorfman, V. B., Pasquini, L., Riudavets, M., López-Costa, J. J., Villegas, A., Troncoso, J. C., Lopera, F., Castaño, E. M., & Morelli, L. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.09.016 · Cited by 90
ABC Transporters Are Key Players in Alzheimer’s Disease
Pereira, C. D., Martins, F., Wiltfang, J., da Cruz e Silva, O. A. B., & Rebelo, S. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170639 · Cited by 93
Functional Roles of the Interaction of APP and Lipoprotein Receptors
Pohlkamp, T., Wasser, C. R., & Herz, J. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00054 · Cited by 92
“Lrp1 binds Aβ, with higher affinity for Aβ40 than Aβ42 (Shibata et al., 2000; Storck et al., 2016).”
Seok, H., Lee, M., Shin, E., Yun, M. R., Lee, Y., Moon, J. H., Kim, E., Lee, P. H., Lee, B., Kang, E. S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40736-x · Cited by 95
Banks, W. A., Robinson, S. M., Verma, S., & Morley, J. E. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00474-3 · Cited by 96
Van Uden, E., Mallory, M., Veinbergs, I., Alford, M., Rockenstein, E., & Masliah, E. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-21-09298.2002 · Cited by 91
“A is one of the proteolytic products of APP metabolism generated from the concerted cleavage at the N- and C-terminal site of the molecule by and secretase, respectively (Checler, 1995; Selkoe et al., 1996; Sinha et al., 2000; Huse and Doms, 2001).”
BackgroundCan sleep apnea cause Alzheimer's disease?
Pan, W., & Kastin, A. J. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.10.019 · Cited by 100
Brain injury-induced dysfunction of the blood brain barrier as a risk for dementia
Abrahamson, E. E., & Ikonomovic, M. D. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113257 · Cited by 86
The missing link in the amyloid cascade of Alzheimer’s disease – Metal ions
Tiiman, A., Palumaa, P., & Tõugu, V. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.01.023 · Cited by 104
“The metal ion homeostasis in the brain is regulated by the BBB (Tamano and Takeda, 2011).”
InfluentialBading, J. R., Yamada, S., Mackic, J. B., Kirkman, L., Miller, C., Calero, M., Ghiso, J., Frangione, B., & Zlokovic, B. V. (2002) · Journal of Drug Targeting · doi:10.1080/10611860290031831 · Cited by 90
“Rapid clearance of Ab40 from the mouse brain (Shibata et al., 2000), rat CSF (Ghersi-Egea et al., 1996) and/or guinea pig CSF and brain (Monro et al., 2002) is not associated with significant metabolism or degradation of peptide in the brain or CSF.”
BackgroundMethodResultSelf-citationCD45 Deficiency Drives Amyloid-β Peptide Oligomers and Neuronal Loss in Alzheimer's Disease Mice
Zhu, Y., Hou, H., Rezai-Zadeh, K., Giunta, B., Ruscin, A., Gemma, C., Jin, J., Dragicevic, N., Bradshaw, P., Rasool, S., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3268-10.2011 · Cited by 88
“A number of studies have shown that the BBB is responsible for elimination of human A from the brain into the blood (Shibata et al., 2000; Shiiki et al., 2004; Terasaki and Ohtsuki, 2005).”
BackgroundYao, Z.-B., Wen, Y.-R., Yang, J.-H., & Wang, X. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.230299 · Cited by 87
“Therefore, few studies argued that the lymphatic clearance of Aβ from the CNS mattered (Shibata et al., 2000; Abbott, 2004), although several studies reported the presence of Aβ in cervical lymphatic nodes (Tsai et al., 2003; Pappolla et al., 2014).”
BackgroundBlood–Brain Barrier and Neurodegenerative Diseases—Modeling with iPSC-Derived Brain Cells
Wu, Y.-C., Sonninen, T.-M., Peltonen, S., Koistinaho, J., & Lehtonen, Š. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147710 · Cited by 89
“In pathological conditions, studies also reveal that brain ECs are able to transport amyloid from the brain to blood through low-density lipoprotein receptor-related protein-1 (LRP1) and receptor for advanced glycation and products (RAGE) [23,24].”
BackgroundInfluentialNeural stem cell therapy for neurovascular injury in Alzheimer's disease
Boese, A. C., Hamblin, M. H., & Lee, J.-P. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113112 · Cited by 86
Fanlo-Ucar, H., Picón-Pagès, P., Herrera-Fernández, V., ILL‐Raga, G., & Muñoz, F. J. (2024) · Antioxidants · doi:10.3390/antiox13101208 · Cited by 105
Clusterin and Alzheimer’s Disease
Calero, M., Rostagno, A. A., Frangione, B., & Ghiso, J. A. (2006) · Springer eBooks · doi:10.1007/0-387-23226-5_14 · Cited by 99
Self-citation
Metadata
- Authors
- Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., & Zlokovic, B. V.
- Affiliations
- University of Southern California (US)
- NYU Langone Health (US)
- Washington University in St. Louis (US)
- American Red Cross (US)
- University of Rochester Medicine (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2000-12-15
- Volume
- 106
- Issue
- 12
- Pages
- 1489-1499
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC387254
- OpenAlex
- W1997822484
- Cited by
- 1,413
- References
- 76
- Citations by year
- 2026: 38 · 2025: 60 · 2024: 58 · 2023: 59 · 2022: 57 · 2021: 75 · 2020: 85 · 2019: 73 · 2018: 52 · 2017: 67 · 2016: 64 · 2015: 56 · 2014: 60 · 2013: 62 · 2012: 60
- FWCI
- 15.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01ag016223-04)
- National Institute on Aging (R37AG005891, R01AG013956, P50AG005142, AG16223, R37AG013956, AG05891)
- National Heart, Lung, and Blood Institute (R01HL050784)
- National Institute of Neurological Disorders and Stroke (NS 33466, R01NS038777)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Aβ40, Alzheimer's disease, blood-brain barrier, LDL receptor-related protein 1, receptor-associated protein, alpha2-macroglobulin, apolipoprotein E, amyloid-beta clearance, efflux transport, cerebral microvasculature, amyloid-beta deposition
- MeSH terms
- Aging, alpha-Macroglobulins, Alzheimer Disease, Amino Acid Sequence, Animals, Apolipoproteins E, Biological Transport, Blood-Brain Barrier, Brain, Catheterization, Genotype, Half-Life, Humans, Immunohistochemistry, Inulin, Iodine Radioisotopes, Kinetics, Male, Mice, Inbred C57BL, Molecular Sequence Data, Peptide Fragments, Receptors, Immunologic, Amyloid beta-Peptides, Mice, Knockout, Low Density Lipoprotein Receptor-Related Protein-1, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.






